Treatment of Acute Myocarditis in Immune Checkpoint Inhibitor (ICI)-Induced Myocarditis

Immune checkpoint inhibitor therapy can cause immune-mediated myocarditis as a serious adverse event. Managing this presentation requires a specific, structured approach distinct from other causes of acute myocarditis.

Clinical scenario: Acute myocarditis arising in the context of immune checkpoint inhibitor (ICI) use — a recognised immune-related adverse event in patients receiving ICI-based oncological therapy.

Treatment Overview

The protocol addresses ICI-induced myocarditis with targeted immunosuppressive strategies, including agents that modulate T-cell activity. The full protocol specifies agent selection, sequencing, and escalation criteria — only a partial summary is available here.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehaf192

ICI-induced myocarditis
If no response in 24–48 h: mycophenolate mofetil, ATG, abatacept, alemtuzumab

View source ↗